Equities

Rapport Therapeutics Inc

RAPP:NMQ

Rapport Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.25
  • Today's Change-0.590 / -2.83%
  • Shares traded221.86k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 202320232022
ASSETS
Cash And Short Term Investments14731
Total Receivables, Net----
Total Inventory----
Prepaid expenses3.310.11
Other current assets, total0.09--
Total current assets15131
Property, plant & equipment, net4.000.34
Goodwill, net----
Intangibles, net----
Long term investments----
Note receivable - long term----
Other long term assets0.55--
Total assets15532
LIABILITIES
Accounts payable2.501.45
Accrued expenses3.200.01
Notes payable/short-term debt00
Current portion long-term debt/capital leases----
Other current liabilities, total3.100.20
Total current liabilities8.801.66
Total long term debt4.2010
Total debt4.2010
Deferred income tax----
Minority interest----
Other liabilities, total1.480
Total liabilities1412
SHAREHOLDERS EQUITY
Common stock0.000.00
Additional paid-in capital200.59
Retained earnings (accumulated deficit)(45)(11)
Treasury stock - common----
Unrealized gain (loss)----
Other equity, total0.00--
Total equity14120
Total liabilities & shareholders' equity15532
Total common shares outstanding3535
Treasury shares - common primary issue00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.